

Chapter 1

Orientation to the research

1.1	INTRODUCTION	1
1.2	THE UNITED ARAB EMIRATES (EMIRATES)	3
1.3	BACKGROUND AND INTEREST	9
1.4	GLOBAL PERSPECTIVE ON MYOCARDIAL INFARCTION	10
1.5	RATIONALE FOR THE STUDY	14
1.6	PROBLEM STATEMENT	15
1.7	AIM OF THE STUDY	16
1.8	RESEARCH QUESTIONS	16
1.9	RESEARCH OBJECTIVES	16
1.10	SIGNIFICANCE OF THE STUDY	17
1.11	RESEARCH DESIGN AND METHODOLOGY	17
1.11.1	Data collection	17
1.11.2	Population	18
1.11.3	Context	19
1.11.4	Data analysis	19
1.11.5	Validity and reliability	19
1.11.6	Scope and limitations.....	20
1.11.7	Ethical considerations	20
1.12	DEFINITIONS OF TERMS USED IN THE STUDY	20
1.12.1	Thrombolytic therapy	20
1.12.2	Acute myocardial infarction (AMI)	21
1.12.3	Barriers	21
1.12.4	Time	21
1.12.5	Delay	22
1.12.6	“Door to needle” time	22
1.13	OUTLINE OF THE STUDY	22
1.14	CONCLUSION	23

Chapter 2

Literature review

2.1	INTRODUCTION	24
2.2	ACUTE MYOCARDIAL INFARCTION	24
2.3	MAJOR BLOOD VESSELS AND ECG RECORDING	26
2.3.1	Major blood vessels	26
2.3.2	The cardiac cycle	27
2.3.3	The electrical activity of the heart	28
2.4	PATHOPHYSIOLOGY OF THE HEART	29
2.5	CLINICAL MANIFESTATIONS	30
2.6	DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION	33
2.7	PAIN EXPERIENCE	38
2.8	MYOCARDIAL INFARCTION MANAGEMENT.....	39
2.8.1	Preservation of the myocardium	39
2.8.2	Pain control	40
2.8.3	Pharmacological therapy	41
2.9	TRIALS AND THROMBOLYTICS	45
2.10	THE IMPORTANCE OF TIME TO THROMBOLYSE	51
2.10.1	Managing complications arising from thrombolytic therapy	55
2.11	BARRIERS TO TIMELY REPERFUSION	57
2.11.1	Prehospital delays	57
2.11.2	In-hospital delays	58
2.11.2.1	Delays at the door (triage time)	59
2.11.2.2	Data-collection time	60
2.11.2.3	Decision to thrombolyse time	60
2.11.2.4	Eligibility criteria	62
2.11.2.5	Drug administration time	64
2.12	MANAGEMENT AND CARE OF PATIENTS	65
2.13	AREA OF THROMBOLYSIS	67

Table of contents		Page
2.14	PREHOSPITAL THROMBOLYSIS	68
2.15	ROLE OF EMERGENCY MEDICAL SERVICES	69
2.16	CONCLUSION	69
Chapter 3		
Research design and methodology		
3.1	INTRODUCTION	70
3.2	RESEARCH DESIGN AND METHODOLOGY	70
3.2.1	Definitions of terms used in the research design and methodology	71
3.2.1.1	Non-experimental	71
3.2.1.2	Descriptive	72
3.2.1.3	Quantitative	72
3.2.1.4	Retrospective study (ex-post facto)	72
3.2.1.5	Cross-sectional design	73
3.3	RESEARCH METHODOLOGY	74
3.3.1	Population and sampling	74
3.3.2	Sampling criteria	74
3.3.3	Eligibility criteria	75
3.3.3.1	Chest pain lasting more than thirty minutes	75
3.3.3.2	Time of presentation	75
3.3.3.3	ECG recording	75
3.3.4	Selection of cases	76
3.3.5	Number of cases	76
3.3.6	Sampling method	76
3.3.7	Context	77
3.3.8	Data collection	77
3.4	CHOICE OF INSTRUMENT	77
3.4.1	Development	78
3.4.2	Types of items in the questionnaire	78
3.4.3	Compilation of the questions	78
3.4.4	Refinement of questions	79
3.4.5	Structure of questionnaire	79

Table of contents		Page
3.5	VALIDITY AND RELIABILITY	79
3.5.1	Validity	80
3.5.2	Reliability	80
3.6	DATA COLLECTION	80
3.7	ETHICAL CONSIDERATIONS	81
3.8	SCOPE AND LIMITATIONS OF THE STUDY	81
3.9	CONTROL OF EXTERNAL VARIABLES	82
3.10	DATA ANALYSIS	82
3.11	CONCLUSION	82

Chapter 4

Data analysis and findings

4.1	INTRODUCTION	83
4.2	DATA COLLECTION	85
4.3	DATA ANALYSIS	86
4.3.1	Section A: Demographic data	86
4.3.1.1	Gender distribution	86
4.3.1.2	Age distribution	87
4.3.1.3	Nationality	88
4.3.1.4	Occupation	89
4.3.1.5	Date and time of arrival	90
4.3.1.6	Accompanied	91
4.3.1.7	Mode of arrival at hospital	92
4.3.1.8	Sections A-5 and A6 Call for ambulance and response to the call for the ambulance	92
4.3.2	Section B	92
4.3.2.1	Past medical and surgical history	93
4.3.2.2	Modifiable risk factors for MI	94
4.3.2.3	Smoking and alcohol use	95

Table of contents		Page
4.3.3	Section C	97
4.3.3.1	Immediate medical condition of the patient	97
4.3.3.2	Severity of pain	98
4.3.3.3	Arrival after symptom onset	98
4.3.3.4	Time of arrival from symptom onset	99
4.3.3.5	Activity during onset of pain	100
4.3.4	Section D	101
4.3.4.1	Door-triage time	101
4.3.4.2	ECG initiated	103
4.3.4.3	Time for ECG monitoring	104
4.3.4.4	Doctors attendance: diagnosis, referral and decision-making	105
4.3.4.5	Delays in the area	106
4.3.4.6	Time to thrombolysis administration	108
4.3.4.7	Commonly used thrombolytic agents	109
4.3.4.8	Area thrombolysis administered	110
4.3.4.9	Admission of patients	111
4.4	SUMMARY OF THE RESULTS	112
4.4.1	The door-to-needle time	112
4.4.2	The symptom-to-needle time	113
4.4.3	The door-at-ECG time	114
4.5	CONCLUSION	114
Chapter 5		
Summary, limitations and recommendations		
5.1	INTRODUCTION	115
5.2	SUMMARY	115
5.2.1	The research process	115
5.2.2	Findings	118
5.2.2.1	What is the extent of the delays facing the AMI patient?	119
5.2.2.2	Where did the delays occur mainly?	119
5.2.2.3	Identify the reasons for the delays	120
5.2.2.4	Is thrombolysis in accordance with the NHAPP recommendation of 30 minutes from "door-to-needle time"?	121
5.3	LIMITATIONS OF THE STUDY	122

Table of contents		Page
5.4	CONCLUSIONS	123
5.4.1	Door-to-ECG collection	123
5.4.2	Is the door-to-needle time in accordance with the NHAAP's recommendation?	124
5.4.3	The symptom-to-needle time	124
5.5	RECOMMENDATIONS	125
5.5.1	To improve patient care	125
5.5.2	Future research	126
5.6	CONCLUSION	126
	BIBLIOGRAPHY	128

Table 1.1	Mortality rates related to acute myocardial infarction (AMI)	1
Table 1.2	AMI mortality rates, 2004	11
Table 2.1	ECG changes and vessels in infarction	37
Table 2.2	Thrombolytic agents currently in use	46
Table 2.3	Thrombolysis in MI (TIMI-1) flow grade	49
Table 2.4	Relationship between time and percentage of cell necrosis	54
Table 2.5	Contraindications for thrombolytic therapy	63
Table 4.1	Nationality	88
Table 4.2	Occupation	89
Table 4.3	Time of arrival from symptom onset	98

List of figures	Page
Figure 1.1 A map of the United Arab Emirates	4
Figure 2.1 Major blood vessels	27
Figure 2.2 Normal ECG recording (PQRS)	28
Figure 2.3 Acute Myocardial Infarction: Injury, ischemia and infarction	30
Figure 2.4 Diagnostic ECG: AMI	35
Figure 4.1 Gender distribution (N = 321)	86
Figure 4.2 Age distributions (N = 321)	87
Figure 4.3 Accompaniment of patient (N = 321)	91
Figure 4.4 Mode of arrival to hospital (N = 321).....	92
Figure 4.5 Medical history (N = 321)	93
Figure 4.6 Modifiable risk factors for myocardial infarction (N=321)	95
Figure 4.7 Smoking as risk factor (N = 321)	95
Figure 4.8 Alcohol use as risk factor (N = 321)	96
Figure 4.9 Immediate medical condition of the patient (N = 321)	97
Figure 4.10 Severity of pain (N = 321)	98
Figure 4.11 Arrival after symptom onset (N = 321)	99
Figure 4.12 Activity during onset of pain (N = 321)	100
Figure 4.13 Treatment of patients (N = 321)	102
Figure 4.14 Acquisition of ECG (N = 321)	103
Figure 4.15 Time for ECG monitoring (N = 321)	104
Figure 4.16 Diagnosis of AMI (N = 321)	105
Figure 4.17 Delays in the area (N=321)	107
Figure 4.18 Time to thrombolysis administration (N = 321)	108
Figure 4.19 Agents currently used	109
Figure 4.20 Area thrombolysis administered	110
Figure 4.21 Admission of patients	111

List of abbreviations

ACC/AHA	American College of Cardiology and American Heart Association
AMI	Acute Myocardial Infarction
ASSENT	Assessment of Safety and Efficacy of New Thrombolytic Investigators
BP	Blood pressure
CABG:	Coronary artery bypasses graft
CINAHL	Cumulative Index to Nursing and Allied Health Literature
CPR	Cardio-pulmonary resuscitation
DM	Diabetes Mellitus
ECG	Electrocardiograph
EMERAS	Estudio Multicentrico Estreptoquinase Republica de America de Sur
EMS	Emergency Medical Service
FTT	Fibrinolytic Therapy Triallist
GISSI	Gruppo Italiano per lo Studio della Streptochinasa nell
GUSTO	Global use of Strategies to Open Occluded Arteries
IHD	Ischemic heart disease
INR	International Nursing Review
ISAM	Intravenous Streptokinase in acute Myocardial Infarction
ISIS	International Study of Infarct Survival
LATE	Late Assessment Thrombolytic Efficiency
MEDLINE	Medical Literature on line
MI	Myocardial infarction
NHAAP	National Heart Attack Alert Program
PTCA	Percutaneous Transcutaneous coronary angiography
PVD	Periphera/Vascular disease
RAPID	Retroplase Angiographic International Dose finding
SAS	Statistical Analyses System
TIMI	Thrombolysis in Myocardial Infarction Trial
TT	Thrombolytic therapy
UAE	United Arab Emirates
UK	United Kingdom
USA	United States of America
WHO	World Health Organization

List of annexures

Annexure A Permission to conduct the study

Annexure B Questionnaire